GlassScriptPhysician profile
Joseph C Peck
NPI 1053368472
$5,569.15
in general payments reported to CMS, 2019-2025
36 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $995 · 2020: $1,543 · 2021: $1,070 · 2022: $561 · 2023: $571 · 2024: $676 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,400.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $945.11 | 2019-2024 | Belbuca, Xtampza |
| Boston Scientific Corporation | $502.88 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Nevro Corp. | $463.32 | 2019-2024 | Senza |
| Abbvie INC. | $378.04 | 2021-2023 | |
| Lundbeck LLC | $304.67 | 2020-2022 | |
| Biodelivery Sciences International, INC. | $275.09 | 2019-2021 | |
| Pfizer INC. | $235.33 | 2019-2024 | |
| Lilly USA, LLC | $217.14 | 2019-2023 | Emgality, Reyvow |
| Horizon Therapeutics Plc | $214.16 | 2019-2020 | |
| Sentynl Therapeutics, INC. | $193.03 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $163.25 | 2019-2021 | |
| Amgen INC. | $163.12 | 2019-2022 | |
| Allergan, INC. | $163.10 | 2020 | |
| Abbott Laboratories | $151.00 | 2020-2022 | |
| Daiichi Sankyo INC. | $141.61 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $135.00 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $110.22 | 2019-2023 | Ztlido |
| Biohaven Pharmaceuticals, INC. | $102.59 | 2021 | |
| Virtus Pharmaceuticals LLC | $86.90 | 2021-2023 | Levorphanol Tartrate |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.08 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $72.79 | 2022 | |
| Redhill Biopharma INC. | $60.89 | 2020-2021 | |
| Grt US Holding, INC. | $56.93 | 2020-2021 | |
| Bioventus LLC | $50.54 | 2021-2022 | |
| Spr Therapeutics, INC | $46.52 | 2023-2024 | Sprint Pns System |
| Radius Health, INC. | $46.24 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $34.29 | 2024 | |
| Valinor Pharma, LLC | $33.16 | 2023 | Movantik |
| Assertio Therapeutics, INC. | $31.49 | 2019 | |
| Almatica Pharma LLC | $21.70 | 2021 | |
| Tactile Systems Technology INC | $20.94 | 2022 | |
| Upsher-Smith Laboratories LLC | $17.02 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.61 | 2022 | |
| Strongbridge US INC. | $13.19 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.02 | 2021 | |
| Zyla Life Sciences, INC. | $11.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Peck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.